"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Telix Pharmaceuticals (NASDAQ:TLX) executives highlighted commercial momentum in prostate cancer imaging and outlined multiple clinical programs in oncology during an H.C. Wainwright discussion ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation. Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

Detailed PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.